Central Pain Study for ABX-1431

Multiple Sclerosis Clinical Trial

Official title: A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of ABX-1431 in Patients With Central Pain

Status Completed

Clinical Trial Summary

This study will determine the safety and tolerability of ABX-1431 in patients with central pain when added on to background pain therapy.

During the course of this study, each participant will take a daily dose of 20 mg of ABX-1431 or a matching placebo for approximately 7 to 9 weeks.

Clinical Trial Description

This is a double-blind, placebo-controlled crossover study, randomized, crossover study of ABX-1431 HCl as add-on therapy in the treatment of central neuropathic pain.The efficacy of ABX-1431 will also be assessed by the change in pain intensity scores using a numerical rating scale (NRS-11).

All patients will undergo a screening visit for enrollment criteria. Eligible patients will be treated with daily medication for 7 to 9 weeks, which will include some treatment with placebo and some treatment with ABX-1431 HCl. Patients will use a web based application to record their daily average pain using a numerical rating scale (NRS-11).

This study will enroll up to 32 patients with chronic central pain due to one of the four following diagnostic groups: Neuromyeliltis Optica Spectrum Disorder (NMOSD), longitudinally extensive transverse myelitis (LETM), Multiple Sclerosis (MS), and Transverse Myelitis (TM). ;

Related Conditions & MeSH terms

• Longitudinally Extensive Transverse Myelitis
• Multiple Sclerosis
• Myelitis
• Myelitis, Transverse
• Neuromyelitis Optica
• Neuromyelitis Optica Spectrum Disorder
• Transverse Myelitis

• NCT number: NCT03138421
• Study type: Interventional
• Source: Abide Therapeutics
• Status: Completed
• Phase: Phase 1
• Start date: August 1, 2017
• Completion date: July 24, 2018